Literature DB >> 12097752

Gordon Murray: heparin, hemodialysis and hubris.

Susan K Fellner1, Mabel L Purkerson.   

Abstract

Gordon Murray (1894-1976), a brilliant and innovative surgeon who spent the majority of his professional career at the University of Toronto, Ont., Canada, is properly credited with having performed the first successful hemodialyses in humans in North America. Neither he nor Kolff, working in the Netherlands, were aware of each other's work during the middle 1940s when wartime hampered communication. Murray's extensive investigations and experience in the use of heparin in vascular surgery laid the groundwork for the use of this anticoagulant with the artificial kidney. He first designed a coil dialyzer in which cellophane tubing was wound about a steel frame. His second-generation apparatus was a plate dialyzer. In all, he performed dialysis on 11 patients with presumed acute renal failure, 50% of whom survived. Those who died succumbed to sepsis or irreversible chronic renal failure. Not much has changed in 50 years. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097752     DOI: 10.1159/000063773

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  5 in total

Review 1.  Anticoagulation in CKD and ESRD.

Authors:  Kelvin Cheuk-Wai Leung; Jennifer Marie MacRae
Journal:  J Nephrol       Date:  2019-01-28       Impact factor: 3.902

2.  Recurrent intradialytic heparin induced anaphylaxis: workup and management.

Authors:  Amelia Santosa; Seng Hoe Tan; Yew Kuang Cheng
Journal:  Asia Pac Allergy       Date:  2013-10-31

Review 3.  Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Authors:  Jenny I Shen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2012-05-05       Impact factor: 8.860

4.  Gene co-expression network analysis identifies the hub genes associated with immune functions for nocturnal hemodialysis in patients with end-stage renal disease.

Authors:  Hongwei Dai; Jiao Zhou; Bo Zhu
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

Review 5.  Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.

Authors:  Frank M P van Haren; Clive Page; John G Laffey; Antonio Artigas; Marta Camprubi-Rimblas; Quentin Nunes; Roger Smith; Janis Shute; Mary Carroll; Julia Tree; Miles Carroll; Dave Singh; Tom Wilkinson; Barry Dixon
Journal:  Crit Care       Date:  2020-07-22       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.